{"context":{"query":">>hgnc>>gwas","source_dataset":"hgnc","target_dataset":"gwas"},"stats":{"queried":1,"total":34,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|mapped_gene|chr_id|p_value","mappings":[{"input":"HGNC:8803","source":"HGNC:8803|platelet derived growth factor receptor alpha","targets":["GCST000136_2|Height|LINC02283|4|4.000000e-07","GCST000585_9|Mean corpuscular volume|LINC02283 - LINC02260|4|2.000000e-29","GCST000587_5|Mean corpuscular hemoglobin|LINC02283 - LINC02260|4|3.000000e-25","GCST000588_1|Red blood cell count|LINC02283 - LINC02260|4|2.000000e-17","GCST001101_2|Corneal curvature|RPL22P13 - PDGFRA|4|1.000000e-09","GCST001339_4|Corneal astigmatism|PDGFRA|4|8.000000e-09","GCST001803_1|Corneal curvature|RPL22P13|4|5.000000e-14","GCST002479_6|Lupus nephritis in systemic lupus erythematosus|GSX2 - RPL22P13|4|5.000000e-07","GCST002502_4|Corneal curvature|RPL22P13 - PDGFRA|4|8.000000e-09","GCST002698_1|Serum VEGFR2 concentration|LNX1 - RPL21P44|4|5.000000e-25","GCST002936_29|Cadmium levels|||1.000000e-06","GCST003264_1475|Post bronchodilator FEV1/FVC ratio|CHIC2 - MORF4L2P1|4|1.000000e-06","GCST003264_227|Post bronchodilator FEV1/FVC ratio|CHIC2 - MORF4L2P1|4|3.000000e-06","GCST003831_12|Asthma|LNX1 - RPL21P44|4|1.000000e-06","GCST003833_22|Adult asthma|LNX1 - RPL21P44|4|1.000000e-06","GCST004332_4|Red blood cell count|LINC02283 - LINC02260|4|4.000000e-10","GCST005803_1|Corneal astigmatism|RPL22P13 - PDGFRA|4|6.000000e-09","GCST005991_10|Platelet count|LINC02283 - LINC02260|4|7.000000e-09","GCST005993_89|Mean corpuscular hemoglobin|LINC02283 - LINC02260|4|6.000000e-109","GCST005994_20|Hematocrit|LINC02283 - LINC02260|4|2.000000e-20","GCST005995_8|Hemoglobin|LINC02283 - LINC02260|4|6.000000e-16","GCST005996_35|Red blood cell count|LINC02283 - LINC02260|4|1.000000e-93","GCST006011_105|Mean corpuscular volume|LINC02283 - LINC02260|4|3.000000e-126","GCST006462_49|Uterine fibroids|GSX2 - RPL22P13|4|9.000000e-10","GCST006585_2369|Blood protein levels|PDGFRA|4|1.000000e-07","GCST006976_71|Macular thickness|GSX2 - RPL22P13|4|8.000000e-10","GCST007267_265|Systolic blood pressure|LNX1 - RPL21P44|4|2.000000e-09","GCST007269_46|Pulse pressure|LNX1 - RPL21P44|4|3.000000e-29","GCST008413_2|Core binding factor acute myeloid leukemia|GSX2 - RPL22P13; PDGFRA; GSX2 - RPL22P13; GSX2 - RPL22P13; GSX2 - RPL22P13; GSX2 - RPL22P13|4;4;4;4;4;4|3.000000e-18","GCST008413_3|Core binding factor acute myeloid leukemia|GSX2 - RPL22P13; PDGFRA; GSX2 - RPL22P13; GSX2 - RPL22P13; GSX2 - RPL22P13; GSX2 - RPL22P13|4;4;4;4;4;4|6.000000e-08","GCST009158_10|Uterine fibroids|LNX1|4|5.000000e-18","GCST009723_52|Vertical cup-disc ratio (adjusted for vertical disc diameter)|PDGFRA|4|4.000000e-12","GCST009724_93|Vertical cup-disc ratio (multi-trait analysis)|GSX2 - RPL22P13|4|1.000000e-15","GCST009724_94|Vertical cup-disc ratio (multi-trait analysis)|RPL22P13 - PDGFRA|4|1.000000e-14"]}]}